Abstract
Invited Lecture AbstractsISPPD-0535 Controlling Pneumococcal Disease Around the Globe: UPDATE FROM AFRICAA. Von Gottberg11South AfricaSouth Africa introduced the seven-valent pneumococcal protein-polysaccharide conjugate vaccine (PCV-7) in 2009 using a novel 3-dose infant schedule (6, 14 and 36 weeks). We assessed PCV-7 impact using national disease surveillance data, accounting for HIV prevention effects. We conducted active, national, laboratory-based surveillance for invasive pneumococcal disease (IPD) from 2005 through 2012, including serotyping and susceptibility testing. We calculated the percentage change in IPD incidence, focusing on individuals aged <2 and 25–44 years, between post-vaccine (2011 and 2012) and pre-vaccine years (average of 2005 through 2008). From 2005 through 2012, 35,192 IPD cases were identified. Rates of PCV-7 vaccine-serotype IPD among children <2 years declined by 89% in 2012, from 32.1 cases per 100,000 person-years to 3.4/100,000 (95% confidence interval [CI], −92% to −86%) while nonvaccine-serotype IPD increased non-significantly from 8.9/100,000 to 9.5/100,000 (+6%; 95% CI, −16% to +23%). Among adults age 25 to 44 years, vaccine serotype IPD declined by 57% (95% CI, −63% to−50% [3.7/100,000 to 1.6/100,000]), compared with smaller nonvaccine serotype IPD declines (3.9/100,000 to 3.5/100,000; −11%, 95% CI, −21% to +4%). Among children <2 years, penicillin-nonsusceptible IPD rates decreased (34.1/100,000 to 6.1/100,000 [−82%; 95% CI, −85% to−78%]). The large reduction in disease caused by vaccine serotypes among both children and adults likely reflects substantial direct and indirect benefits from PCV-7 introduction. The smaller reduction in nonvaccine-serotype IPD suggests HIV prevention efforts are also playing a role in prevention of serious pneumococcal disease.Conflict of interest
Highlights
Pneumococcal conjugate vaccines (PCV7 and pneumococcal conjugate vaccines (PCVs) 13) were introduced into National Immunization Program (NIP) of Uruguay since 2008 showing great impact against hospitalization due to consolidated pneumonia in children
This study demonstrates effectiveness of PCV7 and PCV13 administered in a 2+1 schedule in reducing hospitalizations for consolidated pneumonia in children < 24 months of age in a selected area from Uruguay
We describe a pneumococcal serotype 20 (PS20) outbreak among homeless cases primarily residing in northern Alberta recognized by this surveillance program
Summary
Pneumococcal conjugate vaccines (PCV7 and PCV 13) were introduced into National Immunization Program (NIP) of Uruguay since 2008 showing great impact against hospitalization due to consolidated pneumonia in children. Methods: Invasive pneumococcal disease (i.e., isolation of Streptococcus pneumoniae from blood, cerebrospinal fluid or other normally sterile site) was identified in children age-eligible for ≥1 PCV10 dose through laboratory- and hospital-based surveillance in 10 Brazilian states. Seven-valent pneumococcal conjugate vaccine (PCV7) Introduction to the Israeli national immunization plan (NIP) in Jul-2009 resulted in a fast reduction of PCV7 serotype-specific IPD rate. Conclusion: This is the first Mexican study based on active surveillance, and second in Latin America, that shows early findings of effectiveness of PCV-13 on reduction of overall IPD, and disappearance of pneumococcal serotype 19-A and pneumococcal meningitis in children. We aimed to determine serotype distribution and antibiotic resistance of S. pneumoniae causing invasive disease(IPD) in children in
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
